Lexiscan (regadenoson injection, from CV Therapeutics and Astellas Pharma), a pharmacologic stress agent, has been approved for use in radionuclide myocardial perfusion imaging (MPI) for patients unable to undergo adequate exercise stress.

Lexiscan, an A2A adenosine receptor agonist, produces coronary vasodilation and increases coronary blood flow to help detect and characterize coronary artery disease (CAD). Lexiscan is expected to be available by July 2008.

For more information call (800) 727-7003 or visit www.lexiscan.com.